By Ahmed Aboulenein, Julie Steenhuysen and Michael Erman WASHINGTON (Reuters) -U.S. Health Secretary Robert Kennedy Jr. named ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

The NIH halted its policy requiring universities and research institutes to certify they do not have unlawful diversity, ...

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Unpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

Moderna stock jumped in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine.